Key Developments: Salix Pharmaceuticals Ltd (SLXP.OQ)

SLXP.OQ on NASDAQ Stock Exchange Global Select Market

131.48USD
29 Jul 2014
Price Change (% chg)

$0.16 (+0.12%)
Prev Close
$131.32
Open
$131.75
Day's High
$133.73
Day's Low
$130.43
Volume
215,923
Avg. Vol
346,007
52-wk High
$141.28
52-wk Low
$65.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Salix Pharmaceuticals and Pharming Group NV announces FDA approval of RUCONEST for treatment of acute angioedema attacks in patients with Hereditary Angioedema
Thursday, 17 Jul 2014 01:00am EDT 

Salix Pharmaceuticals Ltd and Pharming Group NV:Says that the Food and Drug Administration has approved RUCONEST (C1 Esterase Inhibitor) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema.Says because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks.  Full Article

Salix Pharmaceuticals to combine with Cosmo Technologies to form Salix Pharmaceuticals plc
Tuesday, 8 Jul 2014 05:00pm EDT 

Salix Pharmaceuticals Ltd:Says the company and Cosmo Pharmaceuticals S.p.A. announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited (Cosmo Tech), a subsidiary of Cosmo.Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market.Transaction is expected to be modestly accretive to Salix's earnings per share in 2016 and increasingly accretive thereafter.  Full Article

Salix Pharmaceuticals Ltd reaffirms FY 2014 guidance; gives Q2 2014 guidance in line with analysts' estimates
Thursday, 8 May 2014 04:02pm EDT 

Salix Pharmaceuticals Ltd:Continues to expect FY 2014 total net product revenue of about $1.6 billion.Continues to expect FY 2014 EBITDA, excluding expenses associated with the acquisition of Santarus, of about $650 million.Continues to expect FY 2014 Non-GAAP net income of about $475 million, or $6.33 per diluted share.Expects Q2 2014 total net product revenue of about $395.0 million.Expects Q2 2014 EBITDA, excluding expenses associated with the acquisition of Santarus, of about $152.7 million.Expects Q2 2014 Non-GAAP net income of about $120.3 million, or $1.63 per diluted share.FY 2014 revenues of $1.6 billion, EBITDA of $672 million, net income of $482 million and EPS of $6.59 - Thomson Reuters I/B/E/S.Q2 2014 revenues of $393 million, EBITDA of $159 million, net income of $125.9 million and EPS of $1.71- Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals Ltd and Progenics Pharmaceuticals announces acceptance of submission to expand use of RELISTOR in Chronic Non-Cancer Pain
Tuesday, 22 Apr 2014 07:00am EDT 

Salix Pharmaceuticals Ltd and Progenics Pharmaceuticals Inc:Submission to European Medicines Agency (EMA) of RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review.If approved, this will add to current marketing authorization in European Union (EU), which allows for use of RELISTOR in advanced illness patients.  Full Article

Salix Pharmaceuticals Inc reaffirms FY 2014 outlook - Conference Call
Tuesday, 11 Mar 2014 04:30pm EDT 

Salix Pharmaceuticals Inc:Expects FY 2014 revenue of $1.6 bln.Expects FY 2014 EBITDA of $650 mln.FY 2014 revenue of $1.6 bln - Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals Ltd gives FY 2014 guidance; EPS guidance above analysts' estimates; Q1 2014 guidance above analysts' estimates - Conference Call
Thursday, 27 Feb 2014 04:02pm EST 

Salix Pharmaceuticals Ltd:Sees FY 2014 product revenue to be about $1.6 bln.Sees FY 2014 non-GAAP fully diluted EPS to be $6.46.Q1 2014 revenue to be about $373 mln.Q1 2014 non-GAAP fully diluted EPS to be $0.85.FY 2014 revenues of $1.6 bln and EPS of $5.98 - Thomson Reuters I/B/E/S.Q1 2014 revenues of $370 mln and EPS $1.35 - Thomson Reuters I/B/E/S.  Full Article

Salix Pharmaceuticals Ltd and RedHill Biopharma announces worldwide license agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
Thursday, 27 Feb 2014 07:43am EST 

Salix Pharmaceuticals Ltd and RedHill Biopharma Ltd:Enters into exclusive agreement.Salix has licensed worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.Financial terms of transaction include upfront payment of $7 mln and $5 mln in subsequent payments to RedHill.  Full Article

Salix Pharmaceuticals Ltd wins Napo Pharmaceuticals litigation
Tuesday, 25 Feb 2014 01:29pm EST 

Salix Pharmaceuticals Ltd:Says that a New York State Supreme Court jury has entered a verdict in its favor in a lawsuit filed against Salix by Napo Pharmaceuticals relating to Fulyzaq.The Jury specifically found that Salix complied with its contractual obligations in commercializing Fulyzaq (crofelemer) in the United States, and thus did not breach the license agreement between the parties.  Full Article

Salix Pharmaceuticals Ltd announces extension of PDUFA action date for ruconest
Monday, 24 Feb 2014 01:00am EST 

Salix Pharmaceuticals Ltd:Salix and Pharming announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA).Says action Date extended to July 16, 2014 for the company's Biologics License Application (BLA) for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.Salix and Pharming are seeking U.S. marketing approval of RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).  Full Article

Salix Pharmaceuticals Ltd announces issuance of U. S. Patent for Rifaximin
Tuesday, 4 Feb 2014 07:00am EST 

Salix Pharmaceuticals Ltd:Says the United States Patent and Trademark Office has issued U.S. Patent No. 8,642,573 entitled "Methods of Treating Hepatic Encephalopathy".Says this patent is eligible for Orange Book listing for the company's hepatic encephalopathy indication and provides protection until Oct. 2029.  Full Article

Salix joins up with Cosmo Pharma's Irish unit for tax savings

ZURICH - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals , the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.

Search Stocks